Positive Data for Cannabis Chewing Gum to be Used in Upcoming IBS Trial

AXIM Biotechnologies, Inc received positive pharmacokinetic (PK) data results for its CanChew Plus cannabidiol (CBD) Gum, according to a company press release.

CanChew Plus is a non-habit forming, hemp-derived CBD functional chewing gum that is available in all 50 states. Currently, AXIM is gearing up for a clinical trial to prove the efficacy of CBD for the treatment of irritable bowel syndrome (IBS).

The single-dose study for 10 mg and 30 mg of CBD determined the concentration of CBD in the blood after chewing CanChew Plus Gum for 30 minutes in healthy participants.

The results of the study showed the 30 mg dosage as the most favorable, and the data will be used to determine the optimal dosage for patients in the IBS trial, according to the release.

“These results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,” said George E. Anastassov, MD, DDS, MBA, chief executive officer of AXIM Biotech. “We believe that we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake. We look forward to entering clinical trial and making available our cannabis-based medicinal solutions to patients suffering from IBS and other gastrointestinal disorders as soon as possible.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Top news of the day from across the health care landscape.
Clobazam oral film (Sympazan) is the first and only FDA-approved oral film formulation to treat seizures associated with Lennox-Gastaut syndrome.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$